Johnson & Johnson Completes Acquisition of Halda Therapeutics, Expanding Next-Generation Oncology Platform
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Halda Therapeutics, bringing Halda’s novel therapeutic platform and clinical-stage oncology programs into Johnson & Johnson’s expanding cancer pipeline. The transaction, valued at approximately $3.05 billion in cash, reinforces J&J’s focus on advancing targeted, innovative cancer treatments.
Introducing a Novel Approach to Targeted Cancer Therapy
Central to the acquisition is Halda’s proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform. The technology is designed to enable highly selective, orally administered therapies that target tumor cells while limiting effects on healthy tissue. This approach aims to address treatment resistance and improve outcomes in cancers that have been difficult to treat with existing modalities.
The deal also includes HLD-0915, Halda’s lead once-daily oral therapy currently in clinical development for prostate cancer, along with additional earlier-stage RIPTAC™ programs targeting other solid tumors.
Strategic Fit Within Johnson & Johnson’s Oncology Portfolio
The acquisition builds on Johnson & Johnson’s long-standing leadership in oncology, particularly in prostate cancer, and aligns with its strategy of integrating breakthrough science into scalable development and commercialization platforms. By combining Halda’s technology with J&J’s global R&D, regulatory, and manufacturing capabilities, the company aims to accelerate clinical development and broaden the reach of next-generation oral cancer therapies.
Financial Impact and Integration
Johnson & Johnson expects the transaction to result in modest dilution to adjusted earnings per share—approximately $0.20 spread across late 2025 and 2026—primarily related to integration costs and employee equity considerations. The company plans to provide additional guidance on the acquisition’s impact during upcoming earnings updates.
Looking Ahead
With the acquisition now complete, Johnson & Johnson will focus on advancing Halda’s clinical programs and exploring the broader potential of the RIPTAC™ platform across multiple cancer indications. Progress in prostate cancer and other solid tumors could further strengthen J&J’s oncology pipeline and expand future treatment options for patients facing resistant disease.
